JP2021519764A5 - - Google Patents

Info

Publication number
JP2021519764A5
JP2021519764A5 JP2020552324A JP2020552324A JP2021519764A5 JP 2021519764 A5 JP2021519764 A5 JP 2021519764A5 JP 2020552324 A JP2020552324 A JP 2020552324A JP 2020552324 A JP2020552324 A JP 2020552324A JP 2021519764 A5 JP2021519764 A5 JP 2021519764A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
membered
nhc
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023917 external-priority patent/WO2019190999A1/en
Publication of JP2021519764A publication Critical patent/JP2021519764A/ja
Publication of JP2021519764A5 publication Critical patent/JP2021519764A5/ja
Pending legal-status Critical Current

Links

JP2020552324A 2018-03-28 2019-03-25 線維性疾患を処置する方法 Pending JP2021519764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649428P 2018-03-28 2018-03-28
US62/649,428 2018-03-28
PCT/US2019/023917 WO2019190999A1 (en) 2018-03-28 2019-03-25 Method of treating fibrotic disease

Publications (2)

Publication Number Publication Date
JP2021519764A JP2021519764A (ja) 2021-08-12
JP2021519764A5 true JP2021519764A5 (https=) 2022-03-31

Family

ID=68060720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552324A Pending JP2021519764A (ja) 2018-03-28 2019-03-25 線維性疾患を処置する方法

Country Status (15)

Country Link
US (1) US20210113560A1 (https=)
EP (1) EP3774785A4 (https=)
JP (1) JP2021519764A (https=)
KR (1) KR20200139721A (https=)
CN (1) CN112166111A (https=)
AU (1) AU2019242595A1 (https=)
BR (1) BR112020019325A2 (https=)
CA (1) CA3093749A1 (https=)
CL (1) CL2020002465A1 (https=)
IL (1) IL277500A (https=)
MX (1) MX2020010034A (https=)
RU (1) RU2020130012A (https=)
SG (1) SG11202008773PA (https=)
TW (1) TW202003503A (https=)
WO (1) WO2019190999A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
RU2020130022A (ru) * 2018-03-28 2022-05-04 Блэйд Терапьютикс, Инк. Модуляторы кальпаина и их терапевтическое применение
BR112020026744A2 (pt) * 2018-06-28 2021-03-30 Blade Therapeutics, Inc. Métodos para tratar fibrose hepática com o uso de inibidores de calpaína
PH12022553378A1 (en) 2020-06-10 2024-03-25 Univ Leuven Kath Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650368A1 (en) * 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
CA2159834A1 (en) * 1993-04-30 1994-11-10 Daniel F. Veber Thrombin inhibitors
AU5526098A (en) * 1996-12-23 1998-07-17 Biochem Pharma Inc. Bicyclic thrombin inhibitors
NZ500620A (en) * 1997-05-02 2000-10-27 Akzo Nobel Nv Synthetic peptides which inhibit serine proteases, specifically thrombin, factor VIIa tissue factor and factor Xa
DE19817459A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
US20100094755A1 (en) * 2008-10-09 2010-04-15 Nelnet Business Solutions, Inc. Providing payment data tokens for online transactions utilizing hosted inline frames
TWI519530B (zh) * 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
JP2013544866A (ja) * 2010-12-09 2013-12-19 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー カルボキサミド化合物及びカルパイン阻害剤vとしてのその使用
SG11201406345XA (en) * 2012-04-03 2014-11-27 Abbvie Deutschland Carboxamide compounds and their use as calpain inhibitors v
WO2014085633A1 (en) * 2012-11-30 2014-06-05 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
WO2018064119A1 (en) * 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
RU2020130022A (ru) * 2018-03-28 2022-05-04 Блэйд Терапьютикс, Инк. Модуляторы кальпаина и их терапевтическое применение

Similar Documents

Publication Publication Date Title
JP2021519764A5 (https=)
ES3031577T3 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
ES2507491T3 (es) Preparación farmacéutica que comprende un inhibidor de DPP-IV y otros agentes terapéuticos de la diabetes en forma concomitante o combinada
JP2021519312A5 (https=)
JP2009514874A5 (https=)
JP2006182786A5 (https=)
EA022040B1 (ru) Применение бетанехола для лечения ксеростомии
JP2008501753A5 (https=)
CN110169962B (zh) 用于治疗癌症的氧烯洛尔组合物
KR20170141757A (ko) 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
RU2020130012A (ru) Способ лечения фиброзного заболевания
JP2021525787A5 (https=)
JP2002537258A5 (https=)
US20160184252A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
JP4011114B2 (ja) 脳浮腫抑制剤
JP2025027020A (ja) 患者において血清リン酸塩を低下させるための組み合わせ
JP2024517769A5 (https=)
JP2023517919A5 (https=)
JP2004517808A5 (https=)
KR101174930B1 (ko) 2-아미노-1,3-프로판디올 화합물의 화합물 제제
JP2020040978A (ja) サルコイドーシスを処置するための1,3−プロパンジスルホン酸またはその薬学的に許容される塩の使用
CN100566719C (zh) 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物
EP3010508B1 (en) Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy
CN116421607A (zh) 1,2,4三唑并4,3-b哒嗪衍生物在制备抗特发性肺纤维化药物中的应用
JPH08165236A (ja) 下痢の予防及び治療剤